A new analysis finds that prior authorization for anti-VEGF therapies increases societal costs despite minimal insurer savings, burdening patients, workplaces, and providers.

Fluid resolution at week 4 seems to translate into longer dosing intervals at week 96 of the PULSAR trial that assessed Eylea ...

Ixo-vec reduced anti-VEGF injection frequency and was well tolerated in patients with wet AMD. A phase 3 pivotal trial ...

IRX-101, a new antiseptic tested in patients receiving eye injections for macular degeneration, resulted in less pain and ...

Homecare Homebase revealed over 4 million patients are denied home health services annually, highlighting critical access issues and the impact of proposed Medicare cuts.